Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · IEX Real-Time Price · USD
0.701
-0.005 (-0.74%)
At close: Apr 18, 2024, 4:00 PM
0.700
-0.001 (-0.09%)
After-hours: Apr 18, 2024, 6:47 PM EDT
Spruce Biosciences Stock Forecast
SPRB's stock price has decreased by -65.47% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Spruce Biosciences stock have an average target of 3.60, with a low estimate of 2.00 and a high estimate of 7.00. The average target predicts an increase of 413.55% from the current stock price of 0.70.
Analyst Consensus: Hold
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
The average analyst rating for SPRB stock from 8 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 2 | 0 | 0 |
Buy | 5 | 5 | 5 | 5 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy → Hold Downgrades $9 → $2 | Buy → Hold | Downgrades | $9 → $2 | +185.31% | Mar 14, 2024 |
JMP Securities | JMP Securities | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +327.96% | Mar 14, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 14, 2024 |
Leerink Partners | Leerink Partners | Buy → Hold Downgrades $9 → $2 | Buy → Hold | Downgrades | $9 → $2 | +185.31% | Mar 14, 2024 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 14, 2024 |
Financial Forecast
Revenue This Year
4.70M
from 10.09M
Decreased by -53.44%
Revenue Next Year
2.55M
from 4.70M
Decreased by -45.71%
EPS This Year
-1.14
from -1.24
EPS Next Year
-1.03
from -1.14
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 12.1M | 10.5M | 568.1M | 328.1M | 291.5M |
Avg | 4.7M | 2.6M | 111.5M | 189.9M | 283.1M |
Low | n/a | n/a | n/a | 113.9M | 272.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 19.7% | 123.5% | 22,176.5% | 194.2% | 53.5% |
Avg | -53.4% | -45.7% | 4,272.2% | 70.4% | 49.1% |
Low | - | - | - | 2.2% | 43.2% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.70 | -0.58 | -0.40 | 5.66 | 1.79 |
Avg | -1.14 | -1.03 | -1.11 | 1.88 | 1.73 |
Low | -1.56 | -1.83 | -2.97 | -0.12 | 1.67 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | -5.1% |
Avg | - | - | - | - | -7.8% |
Low | - | - | - | - | -11.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.